We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

84 hedge funds and large institutions have $106M invested in Syndax Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

35% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 20

17% more funds holding

Funds holding: 72 → 84 (+12)

8.48% less ownership

Funds ownership: 69.53% → 61.05% (-8.5%)

14% less call options, than puts

Call options by funds: $387K | Put options by funds: $448K

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less capital invested

Capital invested by funds: $244M → $106M (-$138M)

Holders
84
Holders Change
+12
Holders Change %
+16.67%
% of All Funds
1.92%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
22
Increased
27
Reduced
20
Closed
10
Calls
$387K
Puts
$448K
Net Calls
-$61K
Net Calls Change
-$299K

Top Buyers

1
BlackRock
BlackRock
New York
+$3.87M
2
SCM
Stonepine Capital Management
Oregon
+$1.95M
3
Macquarie Group
Macquarie Group
Australia
+$1.77M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.58M
5
6CM
683 Capital Management
New York
+$900K

Top Sellers

1
BI
BVF Inc
California
-$19.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.27M
3
SFM
Sphera Funds Management
Israel
-$4.25M
4
OM
Opaleye Management
Massachusetts
-$3.17M
5
ACM
Asymmetry Capital Management
California
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$23.5M -$1.09M -111,356 -3%
MAM
2
MPM Asset Management
Massachusetts
$15.2M – – –
BlackRock
3
BlackRock
New York
$11.7M +$3.87M +394,145 +31%
BI
4
BVF Inc
California
$8.66M -$19.6M -2,000,000 -62%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.36M +$186K +18,996 +3%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$3.93M – – –
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$3.92M +$1.58M +161,146 +41%
O
8
OrbiMed
New York
$3.07M – – –
6CM
9
683 Capital Management
New York
$2.63M +$900K +91,770 +32%
Alyeska Investment Group
10
Alyeska Investment Group
Illinois
$2.38M +$106K +10,834 +3%
JP Morgan Chase
11
JP Morgan Chase
New York
$1.95M -$1.47M -149,779 -35%
Morgan Stanley
12
Morgan Stanley
New York
$1.71M +$32.2K +3,286 +1%
TCM
13
Tekla Capital Management
Massachusetts
$1.4M – – –
SCM
14
Stonepine Capital Management
Oregon
$1.39M +$1.95M +198,373 New
Macquarie Group
15
Macquarie Group
Australia
$1.26M +$1.77M +180,000 New
Northern Trust
16
Northern Trust
Illinois
$1.23M +$306K +31,146 +22%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.18M +$136K +13,835 +9%
State Street
18
State Street
Massachusetts
$1.08M +$236K +24,066 +19%
Millennium Management
19
Millennium Management
New York
$1.05M -$1.89M -192,378 -56%
TAM
20
Tiverton Asset Management
Delaware
$929K – – –
USAA
21
United Services Automobile Association
Texas
$889K -$15.1K -1,535 -1%
BC
22
Boxer Capital
California
$702K – – –
SI
23
Sofinnova Investments
California
$693K +$849K +86,489 +713%
PAM
24
Panagora Asset Management
Massachusetts
$613K +$305K +31,125 +55%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$564K +$333K +33,892 +73%
1
2 3 4

SNDX Hedge Fund Activity: Q2 2018 in Review

84 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2018, worth a combined $106M — down 57% from $244M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new SNDX positions and 10 closed out — a net gain of 12 holders — while 27 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $3.87M. The largest seller was BVF Inc, cutting an estimated $19.6M.

  • 84 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2018, up from 72 in Q1 2018.
  • Funds reported $106M of Syndax Pharmaceuticals stock for Q2 2018, down 57% quarter-over-quarter.
  • 22 funds opened new Syndax Pharmaceuticals positions in Q2 2018 and 10 closed out, a net change of +12 holders.
  • The largest Syndax Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $3.87M added.
  • The largest Syndax Pharmaceuticals seller in Q2 2018 was BVF Inc, an estimated $19.6M sold.

Based on aggregated 13F filings for Q2 2018.